Universidade Federal de Sao Carlos   Report issue

Academic/Hospital Phase 2
Founded: Sao Carlos Brazil (1968)

Organization Overview

First Clinical Trial
2013
NCT02440919
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Larissa Pechincha Ribeiro | Universidade Federal de Sao Carlos

Active Ingredients

Drugs in Phase 2 Trials (1)

ivermectin (stromectol) (1 trial)

Drugs in Other Trials (1)

oxygen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 2)

Infections (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2